Muc1-car-t cells co-expressing btlA / il-18r chimeric receptors, and preparation method and application thereof

By designing MUC1-CAR-T cells that co-express the BTLA/IL-18R chimeric receptor, the problem of the lack of specific targets for CAR-T cells in pancreatic cancer treatment has been solved, significantly enhancing tumor killing ability and immune response, and providing a new treatment option for pancreatic cancer.

CN120624370BActive Publication Date: 2026-05-01SHANGHAI ENTEBIO PHARMACEUTICAL TECHNOLOGY CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
SHANGHAI ENTEBIO PHARMACEUTICAL TECHNOLOGY CO LTD
Filing Date
2025-06-13
Publication Date
2026-05-01

AI Technical Summary

Technical Problem

Existing CAR-T cells lack specific tumor targets in the treatment of solid tumors, leading to serious side effects and limited therapeutic efficacy, especially in pancreatic cancer where they exhibit poor immunosensitivity.

Method used

MUC1-CAR-T cells co-expressing the BTLA/IL-18R chimeric receptor were designed. By linking the extracellular domain of BTLA, the transmembrane region of IL-18R, and the intracellular domain of IL-18R with the MUC1-CAR structure, a BTLA/IL-18R-MUC1-CAR structure was formed, which enhanced the killing, activation, proliferation, and immunosuppressive state of T cells and reduced exhaustion levels.

Benefits of technology

It significantly improved the tumor-killing ability of MUC1-CAR-T cells, enhanced the therapeutic effect of pancreatic cancer, increased the proportion of central memory T cells, reduced T cell exhaustion level, prolonged immune response time, and provided a new immunotherapy strategy for pancreatic cancer.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN120624370B_ABST
    Figure CN120624370B_ABST
Patent Text Reader

Abstract

The application discloses a kind of MUC1-CAR-T cells of co-expression BTLA / IL-18R chimeric receptor and preparation method and application thereof, belong to the field of biological medicine technology.The MUC1-CAR-T cell includes BTLA / IL-18R chimeric receptor and MUC1-CAR structure;The present application uses MUC1 as the targeting molecule of CAR-T cell treatment, the extracellular segment of BTLA is connected with the transmembrane region and intracellular section region of IL-18 receptor, and designs co-expression BTLA / IL-18R chimeric receptor.Experiment verifies and finds that BTLA / IL-18R chimeric receptor can significantly improve the tumor killing ability of MUC1-CAR-T cell, can better inhibit the growth of tumor, provides a new immunotherapy strategy for the treatment of pancreatic cancer.
Need to check novelty before this filing date? Find Prior Art